Voltage-gated sodium (NaV) channels play fundamental roles in initiating and propagating action potentials. NaV1.3 is involved in numerous physiological processes including neuronal development, hormone secretion and pain perception. Here we report structures of human NaV1.3/β1/β2 in complex with clinically-used drug bulleyaconitine A and selective antagonist ICA121431. Bulleyaconitine A is located around domain I-II fenestration, providing the detailed view of the site-2 neurotoxin binding site. It partially blocks ion path and expands the pore-lining helices, elucidating how the bulleyaconitine A reduces peak amplitude but improves channel open probability. In contrast, ICA121431 preferentially binds to activated domain IV voltage-sensor, consequently strengthens the Ile-Phe-Met motif binding to its receptor site, stabilizes the channel in inactivated state, revealing an allosterically inhibitory mechanism of NaV channels. Our results provide structural details of distinct small-molecular modulators binding sites, elucidate molecular mechanisms of their action on NaV channels and pave a way for subtype-selective therapeutic development.
Voltage-gated sodium (NaV) channels generate rapid sodium influx to initiate and propagate action potentials in excitable cells. In mammals, at least nine isoforms of NaVs are expressed with tissue specificity1. NaV1.1, NaV1.2, NaV1.3 and NaV1.6, encoded by SCN1A, SCN2A, SCN3A and SCN8A, are highly expressed in the central nervous system (CNS)2,3. Pathogenic variants of these NaVs are associated with neurological disorders including epilepsy, migraine and neuropathic pain4,5. Emergent evidence indicates NaV1.3 is important for fetal neuronal development, and mutations in NaV1.3 are related to focal epilepsies and polymicrogyria6,7,8. Furthermore, NaV1.3 was found to be highly re-expressed in injured peripheral sensory neurons, and the resulting hyperexcitability may cause neuropathic pain9,10,11. Therefore, NaV1.3 is an important therapeutic target for anti-epilepsy drugs and analgesics.
Eukaryotic NaVs are structurally closely related with each other because they share high amino acid sequence similarity12. NaVs are composed of a large pore-forming α-subunit and regulatory β-subunits. The α-subunit has 24 transmembrane segments organized into four domains (I−IV), each of which contains 6 segments (S1−S6). The first four segments (S1−S4) of each domain form the voltage-sensor domain (VSD), and S5, S6 and the pore-loop between them form the pore module (PM). The intracellular ends of the four pore-lining S6 helices form the activation gate. In addition, the loop connecting DIII and DIV forms the inactivation gate. Four isoforms of β-subunits (β1−β4) are reported to regulate NaVs’ kinetics and cell surface expression13, and they share similar structures with an N-terminal immunoglobulin domain followed by a signal transmembrane segment. Recent advances of structural studies revealed that eukaryotic NaVs share conserved structural features14,15,16,17,18,19. Moreover, multiple natural toxins or clinical-used small-molecule drugs targeting distinct receptor sites in NaVs were revealed at atomic level, which suggest complicated regulatory mechanisms for NaV functions20,21,22,23. To date, most local anesthetic or anti-arrhythmic drugs bind to the central pore of NaVs to block sodium conductance. However, the nearly identical pore regions of different NaVs dampen the enthusiasm in finding isoform-selective drug targeting the pore. As a consequence, new drug binding sites on NaVs and isoform-selective drugs are eagerly awaited to minimize potential off-target side effects.
Natural polypeptide toxins or compounds and synthetic drugs modulate the functions of NaVs via binding to at least 6 distinct receptor sites24. Site-2 neurotoxins are a group of alkaloids with diverse chemical structures25,26, which include plant alkaloids of aconitine (from Aconitum napellus), veratridine (from Liliaceae) and grayanotoxin (from Ericaceae), and batrachotoxin first isolated from the skin of the poison dart frog (Phyllobates aurotaenia). In particular, bulleyaconitine A (designated as BLA hereafter) extracted from the Aconitum bulleyanum plant is an analogue to aconitine. BLA has been prescribed as treatment for chronic pain and rheumatoid arthritis in China since 198527,28. However, the apparent side effects such as causing cardiac arrhythmia and inducing hyperexcitability limit its therapeutic application29. Site-2 neurotoxins have been utilized as useful tools to study NaVs function30. Biophysical studies revealed that the toxins modulate voltage-dependent activation, inactivation and ion selectivity of NaVs31,32,33. They are known to shift the voltage-dependent activation to more negative potential, thus are considered as activators. Meanwhile, the aconitine analogues reduce peak current amplitude. Mutagenesis studies suggested that site-2 toxins share overlapping but not identical sites inside the central pore34,35,36, the detailed binding sites and the underlying modulation mechanisms remain to be fully elucidated. Importantly, synthetic aryl sulfonamide derivates were reported to inhibit NaVs with isoform selectivity at nanomolar potency37. ICA-121431 [2,2-diphenyl-N-(4-(N-thiazol-2-ylsulfamoyl) phenyl) acetamide] (designated as ICA hereafter) selectively inhibits NaV1.3/NaV1.1 with IC50 at ~20 nM, which is up to 1000-fold more potent over other isoforms37. In addition, electrophysiology studies on point mutated NaV variants and the crystal structure of a chimeric sodium channel bound aryl sulfonamide antagonist GX936 showed that these antagonists bind to a site inside the VSDIV38. However, the molecular mechanisms underlying the specific recognition of ICA by NaV1.3 and the inhibition of NaV1.3 remain elusive.
Here, we report the cryo-EM structures of human NaV1.3/β1/β2 in complex with BLA and ICA at 3.3 Å and 3.4 Å, respectively. Together with electrophysiology data, our results demonstrate distinct mechanisms for the modulation of NaV1.3 by the site-2 neurotoxin BLA and the selective antagonist ICA, providing important insights into development of potential isoform-selective drugs.
Functional characterization and overall structure of NaV1.3/β1/β2
We first examined the functional characteristics of human NaV1.3/β1/β2 co-expressed in human embryonic kidney (HEK) 293 cells by whole-cell voltage clamp recording. As illustrated in Fig. 1a, heterologously expressing cells generated robust sodium influx in response to depolarizing pulses and showed fast inactivation within 5 msec. The channel exhibits typical voltage-dependent activation and steady-state fast inactivation with V1/2 of −18.8 ± 0.4 mV and −45.4 ± 1.2 mV, respectively (Fig. 1a), consistent with previous reports8,39,40. The human NaV1.3 and β1/β2 were further co-expressed in HEK293 cells at large scale and purified to homogeneity in detergents (Supplementary Fig. 1). BLA or ICA was added throughout the purification process, respectively. We performed cryo-EM single-particle analysis of the purified NaV1.3/β1/β2 sample (Supplementary Figs. 2–5). The final 3D reconstruction was refined to overall resolution of 3.3 Å and 3.4 Å for NaV1.3/β1/β2-BLA and NaV1.3/β1/β2-ICA, respectively (Supplementary Figs. 2, 4). The cryo-EM density map shows local resolution at 3.0−3.5 Å for both NaV1.3 and β1, indicating stable interaction between them. In contrast, weak and fragmented density for β2 suggests that β2 is mobile or binds weakly to NaV1.3. The high-quality density map allowed us to build reliable models for NaV1.3/β1.
Reminiscent of reported NaV structures16,17,18,19, the pore-forming α-subunit of NaV1.3 is organized in a domain-swapped manner (Fig. 1b). The overall structure of NaV1.3 is similar to the reported mammalian NaV structures with root mean square deviation (RMSD) at ~1.5 Å (Supplementary Table 1). The β1 subunit interacts with α-subunit through extensive interactions between the N-terminal immunoglobulin domain and DI extracellular loop (ECL), as well as packing of the C-terminal TM helix against DIII-S2. Despite relative low resolution for the β2 subunit, the disulfide bond between C55 (β2) and C911 (α) that anchors β2 to the α subunit is clearly revealed (Fig. 1b). Superposition of the NaV1.3/β1/β2-BLA and NaV1.3/β1/β2-ICA structures revealed that they are nearly identical (Supplementary Fig. 6a). All four VSDs displayed activated conformation with three or four gating charges above the hydrophobic constriction site (HCS) (Supplementary Fig. 6b). The inactivation gate IFM motif binds tightly to its receptor site (Supplementary Fig. 6a), resulting in a non-conductive intracellular activation gate with an orifice less than 5 Å in diameter (Fig. 1c, Supplementary Fig. 6a). These structural observations confirmed the NaV1.3 was determined in the inactivated state.
To date, thirteen mutations in NaV1.3 identified from patients are linked to human diseases such as focal epilepsy, some of which cause severe intellectual disability or polymicrogyria6,7,8. Ten of them are mapped on our NaV1.3 structure (Fig. 1d). L247P is reported as a loss of function mutation41, whereas I875T and P1333L are gain of function mutations7. These mutations are located on the S4-S5 linker helix of each domain, which may cause the related diseases by disrupting the coupling of voltage sensing and gating. F1759Y and V1769A are located at the intracellular end of S6IV, which are directly involved in the channel gating. In particular, the gain of function mutant V1769A has been shown to generate large abnormal persistent current at 30% of transient peak current7, that may be caused by the shorter side chain of V1769A leading to uncompleted closure of the activation gate.
Mapping the neurotoxin receptor site-2 recognizing BLA
BLA progressively reduces the peak current amplitude of NaV1.3 in a use-dependent manner (Fig. 2a, b). At 5-Hz frequency, BLA barely inhibited NaV1.3 at the first pulse, however, almost 90% current was blocked after 1000 repetitive pulses (Fig. 2b, right panel; Supplementary Fig. 7a), whereas the control NaV1.3 still generated robust influx after 1000 repetitive pulses (Fig. 2b, left panel). Meanwhile, little inhibition was observed when using a resting-state protocol of holding for 200 sec at −100 mV before test pulse or an inactivation-state protocol including a pre-pulse driving the channel into inactivated state before test pulse (Supplementary Fig. 7b, c). BLA also showed progressive inhibition of NaV1.3 when applied in intracellular solution (Supplementary Fig. 7d). These data suggest BLA preferably binds to open state NaV1.3. Interestingly, BLA elicits minor and persistent current of <5% of ionic peak current at voltage of −50 mV whereas no current is detected without BLA at the same voltage (Fig. 2c). The efficacy of activation by BLA is much weaker than other site-2 neurotoxins such as batrachotoxin or veratridine42. To investigate how BLA modulates NaV1.3, we determined the 3.3 Å cryo-EM structure of NaV1.3/β1/β2 complexed with BLA. Strikingly, unambiguous density located in the central cavity of NaV1.3 close to the fenestration between DI and DII was observed, which fits well with BLA (Fig. 2d, e, Supplementary Fig. 8a). BLA was sequestered in the cavity by extensive polar and non-polar interactions from P-loops and S6 helices from DI and DII. The binding was strengthened by five hydrogen bonds between BLA and carbonyl oxygens of T381, C941 and G942, and sidechains of Q382 and N972 (Fig. 2f). The receptor site is defined by M380, T381, V416, I419 and L420 from DI, and C941, G942, M968, N972 and L976 from DII (Fig. 2f). These interactions make BLA bound so tightly to the receptor site that the binding is nearly irreversible (Supplementary Fig. 7e). Sequence alignment around the receptor site among the nine NaV isoforms showed most of the key residues are identical or highly conserved, which explains the weak selectivity of the BLA (Supplementary Fig. 7g).
Our complex structure revealed a detailed BLA binding site formed by pore modules of DI and DII. Consistent with this structural observation, previous studies showed that mutations at key residues on S6 of DI and DII result in toxin-insensitive phenotypes43. For example, mutations of I433 and L437 (equivalent to V416 and L420 in NaV1.3) on DI-S6, N784 and L788 (equivalent to N972 and L976 in NaV1.3) on DII-S6 of rat NaV1.4 diminished the efficacy of site-2 neurotoxins such as batrachotoxin, grayanotoxin or veratridine34,35,36,44. In our structure, V416, L420, N972 and L976 directly engage BLA, which suggests that these interactions are conserved for the site-2 neurotoxins. No direct interaction from DIII or DIV was observed for BLA binding in our structure. However, residues from S6 helices of DIII and DIV were also reported to be involved in batrachotoxin binding43,45. These data suggest that site-2 neurotoxins share a common site but not identical binding modes, presumably owing to their structural diversity (Supplementary Fig. 7f). Interestingly, local anesthetic and anti-arrhythmic drugs are physical pore-blockers that bind in the central cavity close to S6IV17,21,46. The key residues F1759 and Y1766 are away from BLA at distances of 8.1 Å and 4.3 Å, respectively, which indicates that the receptor site for site-2 neurotoxins is distinct from that for local anesthetic and anti-arrhythmic drugs (Fig. 2g).
Mechanism for activation and inhibition of BLA on NaV1.3
Aconitine and BLA preferably bind to the open state of the channel and reduce peak amplitude in use-dependent manner. Once bound, however, they increase its open probability47. These ostensibly contradictory effects can be explained by our NaV1.3-BLA complex structure. The functionally closed activation gate of the complex structure shows that the gate is too small for BLA to access the central cavity (Figs. 1c and 3a, b). Comparing to the open-state structure of NaVAb48, the open activation gate appears to be large enough for BLA to pass through (Fig. 3c), although one possibility cannot be ruled out that BLA accesses the receptor site through enlarged fenestrations during state transition (Fig. 3a). Once integrating into the receptor site formed by the X-crossing S6 helices and P-loops of DI and DII, BLA physically prevents the shift of the two S6 helices back to the resting state compared to the resting state NaVAb49 (Fig. 3d, e). Superposition of the activation gate between BLA-stabilized NaV1.3 and open NaVAb shows that these two intracellular gates are fairly superimposable (Fig. 3f). We therefore postulate that BLA binding stabilizes the open conformation of S6 of DI and DII at least, which may improve the open probability of the channel. On the other hand, BLA sits underneath the DEKA locus (Fig. 3e), the signature motif that determines sodium selectivity; in addition, three of the five hydrogen-bonds with BLA are attributed to the P-loops of DI and DII (Fig. 2f), implying a mechanism by which BLA analogue aconitine alters ion selectivity of NaV1.450. Furthermore, the bulky BLA partially blocks the ion path, which would surely be an obstacle for conducting hydrated-Na+ (Fig. 3a, b). Our structure demonstrates that BLA binds to the unreported receptor site and stabilizes the open conformation of S6 of DI and DII, meanwhile, it closely interacts with P-loops and partially blocks the ion path resulting in change of ion selectivity and reduction of peak current.
Detailed receptor site in VSDIV determines selectivity of ICA
We next examined the effect of the selective ICA on NaV1.3. ICA exhibited negligible inhibition on NaV1.3 when test pulse was applied at holding potential of −120 mV (Fig. 4a, b). In contrast, ICA almost completely inhibited the inward current of NaV1.3 when the test pulse was proceeded by a protocol to drive the channels into inactivated state (Fig. 4b, right panel). ICA showed strong inactivated state inhibition with IC50 of 95.5 ± 9.3 nM (Fig. 4c). The state-dependent inhibition is consistent with previous report37.
To investigate the selectivity and inhibition mechanism of ICA, we determined the cryo-EM structure of NaV1.3/β1/β2-ICA at 3.4-Å resolution (Fig. 4d, Supplementary Figs. 4–5). Notably, a strong piece of density was found inside the extracellular aqueous cleft of VSDIV, which is absent in the map of NaV1.3/β1/β2-BLA and agrees well with the ICA molecule (Fig. 4e, Supplementary Fig. 8b). The complex structure clearly revealed a detailed receptor site for ICA. The small sidechains of G1603 on S3 helix (G1603S3) and A1626S4 create room to accommodate the thiazole headgroup (Fig. 4f). The anionic thiazole directly interacts with three of six gating charges (i.e., R2−R4) through electrostatic interactions (Fig. 4f). The middle benzene ring contacts L1563S2 and M1604S3 via van der Waals interactions. The protruding diphenyl tail of ICA outside of the binding cleft is further stabilized by R1560S2 and F1605S3. Interestingly, a possible lipid molecule helps to stabilize the hydrophobic tail at a distance of ~4 Å, suggesting that lipid may be involved in this drug-channel interaction (Fig. 4e).
Despite high sequence identity between NaV1.3 and NaV1.7 (Supplementary Table 1, identity at 85.7% among the structures), ICA selectively inhibits NaV1.3/NaV1.1 while another aryl sulfonamide antagonist GX936 selectively inhibits NaV1.738. Overlaying VSDIV of our NaV1.3-ICA with that of the chimeric NaVAb-NaV1.7/VSDIV-GX936 revealed that the interactions between the gating charges R2−R4 and the conserved thiazole group are almost identical in the two structures (Fig. 4g), which suggests that the strong electrostatic interactions between R2−R4 and the delocalized negative-charge of aryl sulfonamide are the key determinants for the potency of the inhibitors. This is consistent with the dramatic potency loss for GX936 when applied to the R4A mutant38. However, the middle benzene ring of ICA would be too close to the bulky side chain of Y1537 in NaV1.7 if replacing S1559 of NaV1.3; similarly, the di-phenyl tail of ICA would directly clash with W1538 in NaV1.7, whereas R1560 in NaV1.3 stabilizes the tail (Fig. 4g). Sequence alignment around the antagonists binding site reveals that S1559 and R1560 of NaV1.3 is only conserved in NaV1.1 among the nine isoforms (Supplementary Fig. 7h). Our structure of the NaV1.3-ICA complex illustrates that, despite high overall structure similarity, S1559 and R1560 are the key determinants for the selective inhibition of ICA on NaV1.3/NaV1.1, which is supported by significant potency reduction of ICA on the S1559Y and R1560W mutants by 9-fold and 33-fold, respectively37.
ICA preferentially binds to activated VSDIV
Comparing the VSDIV of NaV1.3-ICA with that of NaV1.3-BLA showed that the two VSDIV are almost identical, both exhibit activated conformation with four gating charges (R1−R4) above the hydrophobic constriction site (HCS) (Fig. 5a). Most of the key residues around the receptor site assume nearly identical conformations, R4 of NaV1.3-ICA was slightly pulled upward by the anionic thiazole group. This observation suggests that the ICA binding stabilizes VSDIV in the activated conformation. In contrast, when VSDIV of NaV1.3-ICA is aligned with the deactivated VSDIV of rNaV1.5 bound an α-scorpion toxin LqhIII20, many residues interacting with ICA stay at similar positions except for the gating charges (Fig. 5b). In particular, the two helical-turns downward shift of the S4 helix in the deactivated VSDIV would make R1 in close proximity to the anionic thiazole group of ICA. Although it is possible for the R1 to adjust its sidechain to avoid potential clash with the antagonist, lacking of interactions from R2 and R3 destabilizing the ICA binding at the deactivated state. Similarly, alignment between VSDIV of NaV1.3-ICA and the resting state VSD of NaVAb also illustrates that binding of ICA in the resting state is unfavorable due to lacking of the essential interactions from the gating charges (Fig. 5c). Together, these structure comparisons elucidate that ICA preferentially binds to the activated conformation of VSDIV.
Mechanism for inhibition of Nav by aryl sulfonamide antagonist
Fast inactivation is the hallmark property of eukaryotic NaV channels, which closes the channel within 5 msec12. Dozens of mutations targeting fast inactivation gate cause disease-related gain-of-function phenotypes. Mutagenesis studies and high-resolution mammalian NaV structures suggested that the IFM-motif of fast inactivation gate allosterically closes the activation gate by binding to a hydrophobic receptor site near S6IV16 (Fig. 5d). Notably, binding of the IFM-motif is controlled by activation of VSDIV. In other words, stabilizing VSDIV in activated conformation induces the binding the IFM-motif to its receptor site and thus inhibits channel opening, while deactivated VSDIV destabilizes or prohibits the IFM-motif binding and thus enhances channel opening (Fig. 5d). Indeed, in our NaV1.3-ICA structure, ICA binds to and stabilizes the activated VSDIV through multiple interactions including the three gating charges (R2−R4) directly involved. As a result, the IFM-motif binds to its receptor site, and the activation gate becomes non-conductive for hydrated Na+ (Figs. 1c and 5e). This mechanism is likely applicable to other aryl sulfonamide antagonists that inhibit NaVs, because the conserved anionic headgroup engages the conserved gating charges of VSDIV which determines the inhibition potency (Fig. 4f, g). Meanwhile, the chemically varied regions of the antagonists interact with distinct nearby residues which confers the drug isoform selectivity (Fig. 4g). Natural toxins target NaVs and modify channel function. The α-scorpion toxins enhance NaVs opening by trapping VSDIV in deactivated state which destabilizes the binding of IFM-motif to the receptor site (Fig. 5f). The binding of ICA to the deactivated or resting VSD is unfavorable, as a result, ICA exhibits poor inhibition of the channel in resting state (Fig. 4b).
NaV1.3 is widely expressed in the central nervous system and is important for neuronal development. Many pathogenic mutations target NaV1.3 and cause neurological disorders. The nine isoforms of NaVs in human share high amino acid sequence and structure similarity. The central cavity of NaVs harbors receptor sites for local anesthetic/anti-arrhythmic drugs and site-2 neurotoxins. However, the nearly identical chemical environment of the pore makes it less capable for isoform-selective drugs. Here we revealed two high-resolution cryo-EM structures of human NaV1.3/β1/β2 in complex with a non-selective site-2 neurotoxin BLA as well as an isoform-selective antagonist ICA. BLA binds to the highly conserved central cavity, and the receptor site for BLA is tightly packed by the P-loops and S6 helices from DI and DII. BLA accesses to the receptor site likely through the open activation gate, and a constricted gate at the inactivation state or closed gate at resting state surely prevents the entering of the bulky BLA. This structural observation could explain why the site-2 neurotoxins are in favor of binding to open state NaVs. Once bound, BLA stabilizes the open conformation of S6 helices from both DI and DII, and prevents them shifting back to closed conformation. Therefore, BLA can activate NaVs. Meanwhile, the bulky BLA also blocks the ion path leading to reduced peak current. Interestingly, other site-2 neurotoxins such as veratridine and batrachotoxin are more potent in activating NaVs. This is probably because they share overlapping site for activating NaVs, but causing different blockade based on their varied chemical structures. BLA has been used in clinic for the treatment of chronic pain and rheumatoid arthritis for almost four decades in China. Unfortunately, lack of isoform selectivity causes side-effects including cardiac arrhythmia and hyperexcitability, which limits its therapeutic applications. Therefore, finding and verifying new drug binding sites outside the pore is urgently needed for possible selective drug candidates which could help to reduce the off-target effects.
Activation of VSDIV is well-documented to induce fast inactivation of NaV channels. It has been shown that natural α-scorpion toxins target and trap VSDIV in deactivated conformation to prolong channel opening20,51. In contrast, stabilizing VSDIV in activated conformation can extend channel inactivation and therefore inhibit over-excitation. A group of aryl sulfonamide derivates showed promising NaVs inhibition at nanomolar potency, and more importantly with isoform selectivity. For instance, ICA121431 was reported selectively inhibiting NaV1.3 and NaV1.1, while PF-04856264 and GX-936 inhibits NaV1.737. The mechanisms for ICA recognition and selective inhibition of NaV1.3 are illustrated by our cryo-EM structure of NaV1.3/β1/β2-ICA. The structure revealed that the antagonist only binds in the extracellular aqueous cleft of the activated VSDIV but not of the other three VSDs. The anionic headgroup of the antagonist engages the three gating charges on the S4 through electrostatic as well as van der Waals interactions. These interactions trap VSDIV in its activated conformation and thus promote channel inactivation. Therefore, the conserved anionic headgroup determines the potency of the aryl sulfonamide derivates. Meanwhile, the remaining part of ICA is recognized by surrounding sidechains to form a selective receptor pocket, in which S1559 and R1560 are key determinants for the isoform selectivity. Similarly, the varied region of GX-936 fits better within the VSDIV of NaV1.7, and consequently it selectively inhibits NaV1.7 over other isoforms. Comparison of the activated VSDIV of NaV1.3-ICA and the deactivated VSDIV of NaV1.5-LqhIII reveals that ICA indeed preferentially binds to activated VSDIV rather than deactivated or resting conformation. Taken together, our results demonstrate distinct mechanisms for modulation of NaV1.3 by a non-selective site-2 neurotoxin BLA and an isoform-selective antagonist ICA. The structures help to explain the mixed activation and inhibition of NaV1.3 by BLA as well as the potent and selective inhibition of NaV1.3 by ICA at atomic level. These results provide important structural insights into NaVs activation and inactivation, drug blockade, and developing better drugs targeting NaVs with isoform selectivity.
Expression and purification of human NaV1.3/β1/β2 complex
The genes of human NaV1.3 alternative splicing variant 2 (Missing Val625-Glu673, UniProt accession: Q9NY46-2), β1 (Uniprot accession: Q07699) and β2 (Uniprot accession: O60939) were amplified from HEK 293 cDNA library by PCR, which were further subcloned into a modified pEG BacMam vector (Supplementary Table. 2). To monitor protein expression and affinity purification, a mCherry fluorescent protein and a Twin-Strep tag were fused at the C-terminus of NaV1.3. These constructs were confirmed by DNA sequencing. Recombinant baculoviruses were produced in Sf9 insect cells using the Bac-to-Bac baculovirus expression system (Invitrogen, USA). The Sf9 cells were cultured in ESF 921 medium (Expression Systems, USA) at 26 °C and 100 rpm. HEK293F cells were used to express recombinant protein, and were grown at 37 °C in the presence of 1% (v/v) fetal bovine serum in an incubator supplied with 5% CO2 and shaking at 125 rpm. 1% (v/v) P2 baculoviruses of NaV1.3, β1 and β2 were added to the medium when cell density reached 2 × 106 cells/ml. After 8−12 h, sodium butyrate was added to the culture at a final concentration of 10 mM and cells were incubated for another 48 h before harvesting.
The HEK293F cells expressing NaV1.3-β1-β2 complex were harvested and resuspended in buffer A (20 mM HEPES pH 7.5, 150 mM NaCl, 2 mM β-mercaptoethanol (β-ME), and protease inhibitor cocktail including 1 mM phenylmethyl-sulfonyl fluoride (PMSF), 0.8 μM pepstatin, 2 μM leupeptin, 2 μM aprotinin and 1 mM benzamidine). Then the cells were broken by a Dounce homogenizer and the membrane fraction was enriched by ultra-centrifugation at 100,000 × g for 1 h. Subsequently, the membrane proteins were extracted in buffer B (buffer A supplemented with 1% (w/v) n-Dodecyl-β-D-maltoside (DDM), 0.15% (w/v) cholesteryl hemisuccinate (CHS), 5 mM MgCl2 and 5 mM ATP) for 1.5 h at 4 °C with rotation. Insoluble membrane fraction was removed by centrifugation at 100,000 × g for 1 h. Then the NaV1.3-β1-β2 complex was purified using Streptactin Beads, which was pre-equilibrated with buffer C (buffer A supplemented with 5 mM MgCl2, 5 mM ATP and 0.06% (w/v) glyco-diosgenin (GDN)). Subsequently, the beads were washed with 10 column volumes of buffer C and buffer D (buffer C without 5 mM MgCl2 and 5 mM ATP). The protein complex was eluted by 5 ml buffer E (buffer D plus 5 mM desthiobiotin). For NaV1.3-β1-β2-ICA12131 complex, the eluted protein sample was supplemented with 50 μM ICA121431 and concentrated using a 100-kDa cut-off concentrator (Merck Millipore, Germany). The further purification was carried out by size exclusion chromatography (Superose 6 Increase 10/300 GL, GE Healthcare, USA) pre-equilibrated in buffer F (20 mM HEPES pH 7.5, 150 mM NaCl, 2 mM β-ME, 0.007% GDN, 50 μM ICA121431). Peak fractions were collected and concentrated to 4 mg/mL. Before cryo-EM sample preparation, the ICA121431 was added to the concentrated sample at a final concentration of 500 μM.
For NaV1.3-β1-β2-BLA complex, the protein complex was purified similarly as the method described above. Bulleyaconitine A was supplemented throughout the whole purification process except SEC buffer. The final concentration of BLA was at 50 μM for buffer A, B, C and D, 100 μM for buffer E, and 200 μM for buffer F.
Cryo-EM sample preparation and data collection
Purified sample (2.5 μL) was applied to glow-discharged holey cooper grids (Quantifoil, 300 mesh, R1.2/1.3), and then was blotted for 2.0–5.5 s at 100% humidity and 4 °C before being plunged frozen in liquid ethane cooled by liquid nitrogen using a FEI Mark IV Vitrobot. All data were acquired using a Titan Krios transmission electron microscope operated at 300 kV, a Gatan K2 Summit direct detector and Gatan Quantum GIF energy filter with a slit width of 20 eV. All movie stacks were automatically collected using SerialEM at a calibrated magnification of 105,000× with a physical pixel size of 1.04 Å (super-resolution mode). Defocus range was set between −1.2 and −2.2 μm. The dose rate was adjusted to 10 counts/pixel/s, 2424 and 2858 movie stacks were collected for NaV1.3-β1-β2-ICA and NaV1.3-β1-β2-BLA, respectively, each stack was exposed for 6.4 s with 32 frames with a total dose of 60 e-/ Å2.
All the movie stacks were motion-corrected, binned by 2-fold and dose-weighted using MotionCor252, yielding a pixel size of 1.04 Å. Defocus values of each summed micrographs were estimated with Gctf53. Particle picking, 2D classification, 3D classification, polishing and CTF refinement was performed in RELION3.054. A detailed data processing diagram was presented in Supplementary Fig. 2 and 4. The best class containing 175,513 particles for NaV1.3-β1-β2-ICA and 152,431 particles for NaV1.3-β1-β2-BLA were subjected to cisTEM55 and cryoSPARC56 for final refinement, respectively.
The structures of human NaV1.2 (PDB code: 6J8E) alpha subunit and NaV1.7 (PDB code: 6J8H) beta subunits were fitted into the cryo-EM density map of NaV1.3-ICA and NaV1.3-BLA using Chimera57. The models were manually checked and corrected in COOT58 and subsequently refined in Phenix59. The model vs map FSC curves were calculated by Phenix.mtrage. Statistics for cryo-EM data collection and model refinement are summarized in Supplementary Table 3.
Whole-cell voltage-clamp recordings of NaV1.3 in HEK 293 T Cells
HEK 293 T cells were cultured with Dulbecco’s Modified Eagle Medium (DMEM) (Gibco) supplemented with 10% (v/v) fetal bovine serum (FBS) at 37 °C with 5% CO2. HEK 293 T cells were transfected with two recombinant baculoviruses containing genes for NaV1.3-mcherry and β1-eGFP/β2 (the same viruses were used for structural studies) for 12 h, then exchanged fresh DMEM supplemented with 10% FBS and 5 mM sodium butyrate culturing at 30 °C with 5% CO2 for 1–2 day before recording. Electrophysiological experiments were performed to record Na+ current from the NaV1.3 transfected HEK293T cells at room temperature (22−25 °C). Coverslips were placed in the recording chamber within bath solution containing 138 mM NaCl, 10 mM Hepes, 10 mM glucose, 5.4 mM KCl, 2 mM CaCl2 and 1 mM MgCl2 (pH 7.4 adjusted with NaOH). Pipette (2−3 MΩ) were prepared from borosilicate micropipettes by a Sutter P-97 puller and heat-polished before employment. The pipette solution contained 135 mM CsCl, 10 mM Hepes, 10 mM EGTA, 5 mM NaCl and 2 mM MgCl2 (pH 7.4 adjusted with NaOH). Whole-cell voltage clamp recordings were obtained using EPC-10 amplifier (HEKA, Germany), with series resistances <5 MΩ and compensated by 60%. Drugs were diluted with the bath solution to the tested concentrations before recording and applied to the patched cell from pipette electrode with the diameter around 1 μm by puffing around via Picospritzer III microinjector. Data, at the sampling frequency of 20 kHz, were acquired through PatchMaster (HEKA) software and analyzed with Igor 6.2 (WaveMetrics).
All figures were prepared with PyMOL (Schrödinger, LLC) and Prism 8.0.1 (GraphPad Software).
Further information on research design is available in the Nature Research Reporting Summary linked to this article.
The data that support the findings of this study are available from the corresponding author upon reasonable request. Atomic coordinates and corresponding EM maps of the NaV1.3-β1-β2-ICA PDB 7W7F and EMD-32343, and NaV1.3-β1-β2-BLA PDB 7W77 and EMD-32341 have been deposited in the Protein Data Bank (http://www.rcsb.org) and the Electron Microscopy Data Bank (https://www.ebi.ac.uk/pdbe/emdb/), respectively. The data that support the findings of this study are available within the article and its Supplementary Information. Source data of Fig. 1a, Fig. 4c and Supplementary Figs. 1a–b and 7a are provided with this paper. Source data are provided with this paper.
Yu, F. H. & Catterall, W. A. Overview of the voltage-gated sodium channel family. Genome Biol. 4, 207 (2003).
Catterall, W. A., Goldin, A. L. & Waxman, S. G. International Union of Pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels. Pharmacol. Rev. 57, 397–409 (2005).
Goldin, A. L. et al. Nomenclature of voltage-gated sodium channels. Neuron 28, 365–368 (2000).
Lehmann-Horn, F. & Jurkat-Rott, K. Voltage-gated ion channels and hereditary disease. Physiol. Rev. 79, 1317–1372 (1999).
Catterall, W. A. et al. Inherited neuronal ion channelopathies: new windows on complex neurological diseases. J. Neurosci. 28, 11768–11777 (2008).
Vanoye, C. G. et al. Novel SCN3A variants associated with focal epilepsy in children. Neurobiol. Dis. 62, 313–322 (2014).
Zaman, T. et al. Mutations in SCN3A cause early infantile epileptic encephalopathy. Ann. Neurol. 83, 703–717 (2018).
Smith, R. S. et al. Sodium Channel SCN3A (NaV1.3) regulation of human cerebral cortical folding and oral motor development. Neuron 99, 905 (2018).
Hains, B. C. et al. Upregulation of sodium channel NaV1.3 and functional involvement in neuronal hyperexcitability associated with central neuropathic pain after spinal cord injury. J. Neurosci. 23, 8881–8892 (2003).
Lindia, J. A. et al. Relationship between sodium channel NaV1.3 expression and neuropathic pain behavior in rats. Pain 117, 145–153 (2005).
Cummins, T. R. et al. Nav1.3 sodium channels: rapid repriming and slow closed-state inactivation display quantitative differences after expression in a mammalian cell line and in spinal sensory neurons. J. Neurosci. 21, 5952 (2001).
Catterall, W. A. From ionic currents to molecular mechanisms: the structure and function of voltage-gated sodium channels. Neuron 26, 13–25 (2000).
Isom, L. L., De Jongh, K. S. & Catterall, W. A. Auxiliary subunits of voltage-gated ion channels. Neuron 12, 1183–1194 (1994).
Catterall, W. A., Wisedchaisri, G. & Zheng, N. The chemical basis for electrical signaling. Nat. Chem. Biol. 13, 455–463 (2017).
Shen, H. et al. Structure of a eukaryotic voltage-gated sodium channel at near-atomic resolution. Science 355, 924–936 (2017).
Pan, X. et al. Structure of the human voltage-gated sodium channel Nav1.4 in complex with β1. Science 362, aau2486 (2018).
Jiang, D. et al. Structure of the Cardiac Sodium Channel. Cell 180, 122–134 (2020).
Shen, H. et al. Structures of human Nav1.7 channel in complex with auxiliary subunits and animal toxins. Science 363, 1303–1308 (2019).
Pan, X. et al. Molecular basis for pore blockade of human Na+ channel Nav1.2 by the μ-conotoxin KIIIA. Science 363, 1309–1313 (2019).
Jiang, D. et al. Structural basis for voltage-sensor trapping of the cardiac sodium channel by a deathstalker scorpion toxin. Nat. Commun. 12, 128–140 (2021).
Li, Z. et al. Structural Basis for Pore Blockade of the Human Cardiac Sodium Channel Nav1.5 by the Antiarrhythmic Drug Quinidine. Angew. Chem. Int. Ed. Engl. 60, 11474–11480 (2021).
Wisedchaisri, G. et al. Structural Basis for High-Affinity Trapping of the NaV1.7 Channel in Its Resting State by Tarantula Toxin. Mol. Cell 81, 38–48 (2021).
Shen, H. et al. Structural basis for the modulation of voltage-gated sodium channels by animal toxins. Science 362, aau2596 (2018).
Stevens, M., Peigneur, S. & Tytgat, J. Neurotoxins and their binding areas on voltage-gated sodium channels. Front. Pharmacol. 2, 71 (2011).
Wang, S. Y. & Wang, G. K. Voltage-gated sodium channels as primary targets of diverse lipid-soluble neurotoxins. Cell Signal 15, 151–159 (2003).
Catterall, W. A. Cooperative activation of action potential Na+ ionophore by neurotoxins. Proc. Natl Acad. Sci. USA 72, 1782–1786 (1975).
Wang, C. F. et al. Bulleyaconitine A isolated from aconitum plant displays long-acting local anesthetic properties in vitro and in vivo. Anesthesiology 107, 82–90 (2007).
Tang, X. C. et al. Studies on the analgesic action and physical dependence of bulleyaconitine A. Yao Xue Xue Bao 21, 886–891 (1986).
Friese, J. et al. Aconitum sp. alkaloids: the modulation of voltage-dependent Na+ channels, toxicity and antinociceptive properties. Eur. J. Pharmacol. 337, 165–174 (1997).
Khodorov, B. I. Batrachotoxin as a tool to study voltage-sensitive sodium channels of excitable membranes. Prog. Biophys. Mol. Biol. 45, 57–148 (1985).
Catterall, W. A. et al. Voltage-gated ion channels and gating modifier toxins. Toxicon 49, 124–141 (2007).
Ulbricht, W. The effect of veratridine on excitable membranes of nerve and muscle. Ergeb. Physiol. 61, 18–71 (1969).
Quandt, F. N. & Narahashi, T. Modification of single Na+ channels by batrachotoxin. Proc. Natl Acad. Sci. USA 79, 6732–6736 (1982).
Wang, S. Y. & Wang, G. K. Point mutations in segment I-S6 render voltage-gated Na+ channels resistant to batrachotoxin. Proc. Natl Acad. Sci. USA 95, 2653–2658 (1998).
Ishii, H. et al. Point-mutations related to the loss of batrachotoxin binding abolish the grayanotoxin effect in Na(+) channel isoforms. Jpn. J. Physiol. 49, 457–461 (1999).
Wang, G. K. et al. Modification of wild-type and batrachotoxin-resistant muscle mu1 Na+ channels by veratridine. Pflug. Arch. 439, 705–713 (2000).
McCormack, K. et al. Voltage sensor interaction site for selective small molecule inhibitors of voltage-gated sodium channels. Proc. Natl Acad. Sci. USA 110, E2724–E2732 (2013).
Ahuja, S. et al. Structural basis of Nav1.7 inhibition by an isoform-selective small-molecule antagonist. Science 350, aac5464 (2015).
Tang, C. et al. Synergetic action of domain II and IV underlies persistent current generation in Nav1.3 as revealed by a tarantula toxin. Sci. Rep. 5, 9241 (2015).
Meadows, L. S. et al. Functional modulation of human brain Nav1.3 sodium channels, expressed in mammalian cells, by auxiliary beta 1, beta 2 and beta 3 subunits. Neuroscience 114, 745–753 (2002).
Lamar, T. et al. SCN3A deficiency associated with increased seizure susceptibility. Neurobiol. Dis. 102, 38–48 (2017).
Catterall, W. A. Activation of the action potential Na+ ionophore by neurotoxins. An allosteric model. J. Biol. Chem. 252, 8669–8676 (1977).
Deuis, J. R. et al. The pharmacology of voltage-gated sodium channel activators. Neuropharmacology 127, 87–108 (2017).
Wang, S. Y., Barile, M. & Wang, G. K. Disparate role of Na(+) channel D2-S6 residues in batrachotoxin and local anesthetic action. Mol. Pharmacol. 59, 1100–1107 (2001).
Wang, S. Y. & Wang, G. K. Batrachotoxin-resistant Na+ channels derived from point mutations in transmembrane segment D4-S6. Biophys. J. 76, 3141–3149 (1999).
Jiang, D. et al. Open-state structure and pore gating mechanism of the cardiac sodium channel. Cell 184, 5151–5162 (2021).
Grishchenko, I. I., Naumov, A. P. & Zubov, A. N. Gating and selectivity of aconitine-modified sodium channels in neuroblastoma cells. Neuroscience 9, 549–554 (1983).
Lenaeus, M. J. et al. Structures of closed and open states of a voltage-gated sodium channel. Proc. Natl Acad. Sci. USA 114, E3051–E3060 (2017).
Wisedchaisri, G. et al. Resting-state structure and gating mechanism of a voltage-gated sodium channel. Cell 178, 993–1003 (2019).
Campbell, D. T. Modified kinetics and selectivity of sodium channels in frog skeletal muscle fibers treated with aconitine. J. Gen. Physiol. 80, 713–731 (1982).
Clairfeuille, T. et al. Structural basis of α-scorpion toxin action on Nav channels. Science 363, eaav8573 (2019).
Zheng, S. Q. et al. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat. Methods 14, 331–332 (2017).
Zhang, K. Gctf: Real-time CTF determination and correction. J. Struct. Biol. 193, 1–12 (2016).
Zivanov, J. et al. New tools for automated high-resolution cryo-EM structure determination in RELION-3. Elife 7, e42166 (2018).
Grant, T., Rohou, A. & Grigorieff, N. cisTEM, user-friendly software for single-particle image processing. Elife 7, e35383 (2018).
Punjani, A. et al. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290–296 (2017).
Pettersen, E. F. et al. UCSF Chimera–a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605–1612 (2004).
Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D. Biol. Crystallogr. 60, 2126–2132 (2004).
Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D. Biol. Crystallogr. 66, 213–221 (2010).
We thank X. Huang, B. Zhu, X. Li, L. Chen, and other staff members at the Center for Biological Imaging (CBI), Core Facilities for Protein Science at the Institute of Biophysics, Chinese Academy of Science (IBP, CAS) for the support in cryo-EM data collection. We thank Yunlong Qiu, Yue Li, and Zhuoya Yu for their helpful discussions, Yan Wu for his research assistant service. This work is funded by Institute of Physics, Chinese Academy of Sciences (E0VK101 to D.J.), Chinese Academy of Sciences Strategic Priority Research Program (Grant XDB37030304 to Y.Z. and Grant XDB37030301 to X.C.Z.), the National Key Research and Development Program of China (Grant 2021YFA1301501 to Y.Z.), the National Natural Science Foundation of China (Grant 92157102 to Y.Z.), the National Natural Science Foundation of China (31971134 to X.C.Z.), the National Natural Science Foundation Regional Innovation and Development Joint Fund (U20A6005 to J.S.), and the Ministry of Science and Technology of the People´s Republic of China (2021ZD0203800 to S.Z.).
The authors declare no competing interests.
Peer review information
Nature Communications thanks Christopher Ahern and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Li, X., Xu, F., Xu, H. et al. Structural basis for modulation of human NaV1.3 by clinical drug and selective antagonist. Nat Commun 13, 1286 (2022). https://doi.org/10.1038/s41467-022-28808-5
This article is cited by
Journal of Cheminformatics (2022)
Nature Structural & Molecular Biology (2022)